Standard BioTools Inc (NASDAQ:LAB) shares, rose in value on Wednesday, July 09, with the stock price up by 4.62% to the previous day’s close as strong demand from buyers drove the stock to $1.36.
Actively observing the price movement in the last trading, the stock closed the session at $1.3, falling within a range of $1.2801 and $1.41. The value of beta (5-year monthly) was 1.505. Referring to stock’s 52-week performance, its high was $2.41, and the low was $0.92. On the whole, LAB has fluctuated by 28.30% over the past month.
With the market capitalization of Standard BioTools Inc currently standing at about $516.56 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-06.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 169.13M, with a low estimate of 37.2M and a high estimate of 41.7M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 39.83M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LAB’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of LAB currently trading nearly 14.14% and 21.33% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 62.96, while the 7-day volatility ratio is showing 6.88% which for the 30-day chart, stands at 8.36%. Furthermore, Standard BioTools Inc (LAB)’s beta value is 1.30.
A comparison of Standard BioTools Inc (LAB) with its peers suggests the former has fared considerably weaker in the market. LAB showed an intraday change of 4.62% in last session, and over the past year, it shrunk by -22.29%%.
Data on historical trading for Standard BioTools Inc (NASDAQ:LAB) indicates that the trading volumes over the past 10 days have averaged 2.17 and over the past 3 months, they’ve averaged 1.74 million. According to company’s latest data on outstanding shares, there are 379.09 million shares outstanding.
Nearly 3.18% of Standard BioTools Inc’s shares belong to company insiders and institutional investors own 72.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 16.16 million shares as on 2025-06-13, resulting in a short ratio of 11.03. According to the data, the short interest in Standard BioTools Inc (LAB) stood at 725.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 17.49 million. The stock has fallen by -26.88% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LAB stock heading into the next quarter.
